Luzhou Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou 646000, China.
State Key Laboratory of Biotherapy, West China Hospital of Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.
Oxid Med Cell Longev. 2022 Dec 16;2022:2764940. doi: 10.1155/2022/2764940. eCollection 2022.
KIF11 is one of the 45 family members of kinesin superfamily proteins that functions as a motor protein in mitosis. Emerging evidence revealed that KIF11 plays pivotal roles in cancer initiation, development, and progression. However, the prognostic, oncological, and immunological values of KIF11 have not been comprehensively explored in pan-cancer. In present study, we comprehensively interrogated the role of KIF11 in tumor progression, tumor stemness, genomic heterogeneity, tumor immune infiltration, immune evasion, therapy response, and prognosis of cohorts from various cancer types. In general, KIF11 was significantly upregulated in tumors compared with paired normal tissues. KIF11 showed strong relationships with pathological stage, prognosis, tumor stemness, genomic heterogeneity, neoantigens, ESTIMATE, immune checkpoint, and drug sensitivity. The methylation level of KIF11 decreased in most cancers and was correlated with the survival probability in different human cancers. The expression of KIF11 was diverse in different molecular and immune subtypes and remarkably correlated with immune cell infiltration in the tumor microenvironment. Comparative study revealed that KIF11 was a powerful biomarker and associated with immune, targeted, and chemotherapeutic outcomes in various cancers. In addition, KIF11 interaction and coexpression networks mainly participated in the regulation of cell cycle, cell division, p53 signaling pathway, DNA repair and recombination, chromatin organization, antigen processing and presentation, and drug resistance. Our pan-cancer analysis provides a comprehensive understanding of the functions of KIF11 in oncogenesis, progression, and therapy in different cancers. KIF11 may serve as a potential prognostic and immunological pan-cancer biomarker. Moreover, KIF11 could be a novel target for tumor immunotherapy.
KIF11 是驱动蛋白超家族蛋白的 45 个家族成员之一，在有丝分裂中作为一种马达蛋白发挥作用。新出现的证据表明，KIF11 在癌症的发生、发展和进展中起着关键作用。然而，KIF11 在泛癌中的预后、肿瘤学和免疫学价值尚未得到全面探讨。在本研究中，我们全面探讨了 KIF11 在肿瘤进展、肿瘤干性、基因组异质性、肿瘤免疫浸润、免疫逃逸、治疗反应和来自不同癌症类型队列的预后中的作用。总的来说，与配对的正常组织相比，肿瘤中 KIF11 的表达显著上调。KIF11 与病理分期、预后、肿瘤干性、基因组异质性、新抗原、ESTIMATE、免疫检查点和药物敏感性有很强的相关性。KIF11 的甲基化水平在大多数癌症中降低，与不同人类癌症的生存概率相关。KIF11 在不同的分子和免疫亚型中的表达不同，与肿瘤微环境中的免疫细胞浸润显著相关。比较研究表明，KIF11 是一种强有力的生物标志物，与各种癌症中的免疫、靶向和化疗结果相关。此外，KIF11 的相互作用和共表达网络主要参与细胞周期、细胞分裂、p53 信号通路、DNA 修复和重组、染色质组织、抗原处理和呈递以及耐药性的调节。我们的泛癌分析提供了对 KIF11 在不同癌症发生、进展和治疗中的功能的全面理解。KIF11 可能成为一种潜在的预后和免疫泛癌生物标志物。此外，KIF11 可能成为肿瘤免疫治疗的新靶点。
